292 related articles for article (PubMed ID: 22186794)
1. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
3. Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1.
Cai J; Lin K; Cai W; Lin Y; Liu X; Guo L; Zhang J; Xu W; Lin Z; Wong CW; Sander M; Hu J; Yan G; Zhu W; Liang J
Mol Oncol; 2020 Dec; 14(12):3153-3168. PubMed ID: 33037696
[TBL] [Abstract][Full Text] [Related]
4. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
[TBL] [Abstract][Full Text] [Related]
5. Application of Oncolytic Poxviruses: An Emerging Paradigm in Cancer Therapy.
Chakraborty P; Kumar R; Karn S; Raviya DD; Mondal P
Adv Exp Med Biol; 2024; 1451():369-381. PubMed ID: 38801591
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer.
Cousin S; Toulmonde M; Kind M; Guegan JP; Bessede A; Cantarel C; Bellera C; Italiano A
Exp Hematol Oncol; 2022 Dec; 11(1):104. PubMed ID: 36474303
[TBL] [Abstract][Full Text] [Related]
7. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Toulmonde M; Guegan JP; Spalato-Ceruso M; Peyraud F; Kind M; Vanhersecke L; Le Loarer F; Perret R; Cantarel C; Bellera C; Bessede A; Italiano A
Mol Cancer; 2024 Feb; 23(1):38. PubMed ID: 38378555
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.
Koval O; Kochneva G; Tkachenko A; Troitskaya O; Sivolobova G; Grazhdantseva A; Nushtaeva A; Kuligina E; Richter V
Biomed Res Int; 2017; 2017():3620510. PubMed ID: 28951871
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Poxviruses.
Chan WM; McFadden G
Annu Rev Virol; 2014 Sep; 1(1):119-141. PubMed ID: 25839047
[TBL] [Abstract][Full Text] [Related]
10. Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1.
Hoang HD; Said A; Vaidya N; Gilchrist VH; Malone K; Kabilan U; Topshee S; Xiang X; Yang AD; Olagnier D; Mossman K; Beug ST; Jafarnejad SM; Workenhe ST; Graber TE; Alain T
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36958764
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma.
Toulmonde M; Cousin S; Kind M; Guegan JP; Bessede A; Le Loarer F; Perret R; Cantarel C; Bellera C; Italiano A
J Hematol Oncol; 2022 Oct; 15(1):149. PubMed ID: 36271420
[TBL] [Abstract][Full Text] [Related]
12. Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis.
Jo HH; Chun SJ; Yoo JJ; Lee MH; Kim SG; Kim YS
J Liver Cancer; 2020 Sep; 20(2):177-182. PubMed ID: 37384323
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic potential of oncolytic vaccinia virus.
Thorne SH
Front Oncol; 2014; 4():155. PubMed ID: 24987615
[TBL] [Abstract][Full Text] [Related]
14. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
[TBL] [Abstract][Full Text] [Related]
15. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Breitbach CJ; Moon A; Burke J; Hwang TH; Kirn DH
Methods Mol Biol; 2015; 1317():343-57. PubMed ID: 26072416
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
[TBL] [Abstract][Full Text] [Related]
18. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.
Downs-Canner S; Guo ZS; Ravindranathan R; Breitbach CJ; O'Malley ME; Jones HL; Moon A; McCart JA; Shuai Y; Zeh HJ; Bartlett DL
Mol Ther; 2016 Aug; 24(8):1492-501. PubMed ID: 27203445
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
